Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101881 | 0.81 | ADRB2 (0.36) | ALDH1A1MRGPRX4BRD4MAOAMAOB | |
| SCHEMBL7098736 | 0.80 | ALDH1A1 (0.41) | ALDH1A1BRD4MEN1KMT2AHPGD | |
| SCHEMBL11081223 | 0.79 | ALDH1A1 (0.39) | ALDH1A1BRD4MEN1KMT2AHPGD | |
| SCHEMBL11722709 | 0.76 | BRD4 (0.47) | ALDH1A1MRGPRX4BRD4MAOAMAOB | |
| SCHEMBL7097701 | 0.71 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1MEN1KMT2AHPGD | |
| SCHEMBL7103398 | 0.70 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1MEN1KMT2AHPGD | |
| SCHEMBL5886479 | 0.68 | BRD4 (0.44) | MRGPRX4BRD4MAOAMAOB | |
| SCHEMBL12808838 | 0.66 | ALDH1A1 (0.60) | ALDH1A1L3MBTL1MEN1KMT2AHPGD | |
| SCHEMBL9385104 | 0.66 | L3MBTL1 (0.53) | ALDH1A1L3MBTL1MEN1KMT2ANR3C1 | |
| SCHEMBL7625970 | 0.66 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| US-6503935-B1 | Treating urinary incontinence or retrograde ejaculation | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | ALDH1A1 263/4885MRGPRX4 185/4885BRD4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.